Navigation Links
Point Of Care Testing (POCT) Information System

ProductsPoint Of Care Testing (POCT) Information System
Company Telcor
Item Point Of Care Testing (POCT) Information System
Features Quick-Linc is the POCT Interface Engine that connects results from tests performed at the point of care to the Electronic Medical Record.
  • Connect multiple POCT devices and / or Data Management System (DMS) into a single system and a single output
  • Send POCT results via a NCCLS POCT1-A compliant HL7 EDI or Script
  • Patient ID validation, repeat processing, order / result code translations and hundreds of other configuration options
  • Multiple outputs to multiple systems in a multi-facility environment
  • Easily add new POCT devices and / or DMS
  • Easily upgrade to QML for centralized Operator, Device, QC, and Utilization monitoring*
Description POCT, which includes bed side and near patient testing is growing 13 to 17% a year. This growth has posed unique problems for hospitals and clinical laboratories by shifting workflow and quality responsibility to decentralized areas focused on patient care rather than testing disciplines. Compounding the problem is the reality of controlling staffing costs as hospital reimbursement rates continue to decline or hold steady in the best of times.

The POCT Coordinators responsibility to ensure compliance of devices and operators increases as new device types from new vendors are deployed through out the hospital. These responsibilities, coupled with the need to capture charges for billing and revenue cost reporting, are increasing the work requirements of the POCT Coordinator to an unrealistic level.

POCT accomplishes the goal of rapid turnaround of results for patient treatment. However, without integrating the data into the patients clinical record, the caregivers are deprived of a readily accessible, comprehensive view of all clinical data to support their decision making.

The TELCOR Quick-Linc and QML products successfully address these specialized user requirements. They provide a cost saving way to integrate the data into the Laboratory/Clinical Information System and provide all operator, device, and QC data in a format that reduces the labor needed to monitor and control the POCT program.

Our approach is to provide a scalable solution with an upgrade path that eliminates throw away costs, as well as the redundant costs of maintaining multiple systems with multiple interfaces. A TELCOR client can start with Quick-Linc interfacing one or more POCT vendors data management systems to the clients information system. The client can continue to expand the system with new vendor devices and consolidate the data management functions by upgrading to QML, without replacing any of the functions and cost of the Quick-Linc module.

Info Telcor
Customer Service: (402) 489-1207
Web site: http://www.telcorinc.com/

Related medicine products :

1. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
2. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Straight)
3. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 90)
4. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 135)
5. Spanish Near Point Card
6. Lebensohn Near Point Chart
7. Contemporary Near Point Card
8. Wormington Near Point Card
9. Near Point Card 4 1/2 to 24 PT - BC2202
10. Near Point Diagnostic Card Set - BC11982
11. Near Point Card/Newspaper 8 to 48 - BC2203
This handheld reference is a practical guide to established surgical oncology principles for each organ system.
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons.
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician.
Medicine Products:
(Date:5/16/2008)...R, Minn., May 16 /PRNewswire-USNewswire/ -- This r...Mayo Clinic in conjunction with the,National Cance...udy being presented at the American Society of Cli..., may change treatment practice,in about 25 percen...or,proposed changes to the way colorectal cancers ...
(Date:5/16/2008)... Covers More than 500 Workers, WASHINGTON, May 16...cs,and emergency medical technicians in the Greate...have ratified their first-ever contract as,Teamste...s are now covered by a,strong contract that gives ...," said Teamsters General President Jim Hoffa., T...
(Date:5/16/2008)...rom an international, multicenter Phase III clinic...therapy everolimus (RAD001) significantly delays c...ey cancer whose disease had worsened on other trea...n attending physician at Memorial Sloan-Kettering ...gs on May 31 at the annual meeting of the American...
(Date:5/16/2008)...n) Declaring that Primary care medicine is in a p...dent of the American College of Physicians (ACP), ...oyers and consumers to issue a call for comprehens... internists and other primary care physicians. ,...y care medicine in the U.S., Dr. Dale and other pa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...revent, a powdered medication inhaled by asthma pa...us of an FDA Pulmonary-Allergy Drugs Advisory Comm...aths related to asthmatic symptoms in patients who...FDA documents released yesterday indicate that abo...
...ase III clinical trial of Ruboxistaurin (RBX) at a... inhibit Protein kinase C (PKC) – beta inhibitor, ...ith diabetes. The study was conducted in 252 pat...the Research team of Joslin Diabetes Centre across...
...e incidence of asthma, hay fever or any of the all...f brain cancer that may be fatal. Variations in ce...ore prone to the attacks of asthma and other aller...ns also prevent the incidence of the most common f...
... interesting study done in Nepal and India has sho...stoves is associated with increased risk of develo...ct has been found to be widely prevalent in develo... present study examined the association between co...
Other Medicine News:
(Date:5/15/2008)...BRIDGEWATER, N.J., May 15 /...ounced today that findings from the,landmark ATHEN...l therapy,for the treatment of patients with atria...sk of cardiovascular hospitalizations or death fro...0.00000002), meeting the study,primary endpoint. T...
(Date:5/15/2008)...BOSTON, May 15 /- CenterWatch, a publ... market research about clinical,trials, finds that...e EDC,(electronic data capture) systems. More than... indicated that they had been trained on three or ...d that the effectiveness of,their EDC training had...
(Date:5/15/2008)...care Advantage Fee-For-Service Plan Positions Blue...iness, According to a New Report from ...enn., May 15 /- HealthLeaders-InterSt...ntelligence, reports that as the,economy continues...f,Michigan remains the best equipped of all of its...
(Date:5/15/2008)...GREEN BAY, Wis., May 15 /- Omega 3 fa...rther considered as a credible natural,alternative...ADHD patients,recent in vivo French study reveals...ffects of omega-3 in hyperactivity, French researc...e specific positive effects on,impulse control., ...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Congenital heart defects increasing among IVF twins 10631 1Congenital heart defects increasing among IVF twins 10631 2Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 1Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 1Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 3Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 4Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 1Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 2
...INNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-ye...III trial confirm the positive,clinical profile of...ring to nearly 1,300 the number of Endeavor patien...ficantly, among those 1,300,Endeavor patients, the...bosis using the independent, pre-specified clinica...
... Company Set to Host Evening Symposium at ATC -,...nced today that,an independent data monitoring c...data from the Phase 2b kidney transplant (PROMISE)...proximately 1/3 of,the anticipated 332 patients ... trial continue according to the original study,...
Other Medicine Technology:Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 2Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 4